News | December 07, 2012

SFA Stents Show Acceptable Long Term Patency

December 7, 2012 — More than half of patients treated for claudication or critical limb ischemia (CLI) with stenting of the superficial femoral artery (SFA) had primary patency at five years.

“Stenting of the SFA is associated with an acceptable success rate even after five years and in patients with long SFA lesions,” noted Giovanni Torsello, M.D., at the 39th annual VEITHsymposium.

Primary patency rates for 517 patients were, respectively, 86 percent, 75 percent and 61 percent at one, three and five years. Primary patency was defined as the absence of hemodynamically-significant stenosis on duplex ultrasound imaging (systolic velocity ratio <2.4) at the target lesion and without target lesion revascularization (TLR). There were no significant difference between TASC A/B and TASC C/D lesions groups or between bare-metal stents and drug-eluting, said Torsello, who is the chief of the department of vascular surgery at St. Franziskus-Hospital in Münster, Germany.

The results come from a retrospective review of 517 patients who reached a follow-up of at least 2 years. Overall 827 stents were implanted in 543 limbs.

More than three quarters of patients (77.9 percent) were treated for claudication, and the remaining patients were treated for CLI. TASC II C or D lesions were seen in 35.5 percent of patients, based on angiography. Complete occlusion in was seen in 42.7 percent and 13.8 percent had popliteal involvement. The average lesion length was 154.2 ±94.0 mm. After a mean follow-up of 93.4 ±1.6 months, 18.8 percent of patients died.  Mean ankle-brachial index increased from 0.67 ±0.17 to 0.98±1.7 at follow up (p<0.001). TLR was performed in 27.8 percent of the limbs treated. In addition, secondary patency rates were 95 percent, 90 percent and 76 percent after one, three and five years. Eight patients (1.5 percent) underwent major amputation.

For more information: www.veithpress.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now